Weekly Roundup: August 31- September 4

September 4, 2020

ICYMI, some of the content featured this week includes articles about a new adapalene gel for acne vulgaris, if preservatives like parabens are actually safe in cosmetics, characteristics that can help distinguish facial hyperpigmentation disorders, valuable information about vitiligo treatment with expert Seemal R. Desai, M.D., FAAD, plus more.

In case you missed it, some of this week’s featured content includes a glimpse into the world of vitiligo treatment with expert Seemal R. Desai, M.D., FAAD, the launch of a new adapalene gel for treatment of acne vulgaris, characteristics that can help distinguish facial hyperpigmentation disorders, how sunscreen showed strong therapeutic properties in patients with pigmentary disorders, if preservatives like parabens are actually safe in cosmetics, plus more.

How safe are cosmetics?

Zoe Diana Draelos, M.D., explains the role of preservatives in skincare products and the general safety and efficacy of products when it comes to protecting the skin against environmental factors.

Vitiligo subtypes indicate unstable, active disease

Subtypes such as confetti vitiligo and trichrome vitiligo can be signs of unstable active disease, says expert Seemal R. Desai, M.D., FAAD.

The Mainstream Patient: August 31

This week’s edition of The Mainstream Patient features stories about a newly approved acne treatment, strawberry legs, coconut oil in skincare, if your acne might possibly be rosacea, plus more

Will OSHA cite me for requesting employees not wear masks?

While several employees wanted to wear masks upon his office reopening, Dr. Covid reminded them that their state governor and city mayor did not require their use. Now an employee has contracted COVID-19 from a patient and has filed a complaint with the Occupational Safety and Health Administration. Should he be concerned?

Advances in vitiligo give patients hope

Vitiligo can be psychologically devastating for patients. Expert Seemal R. Desai, M.D., FAAD, shares how recent advances in vitiligo treatment offer hope to patients impacted by the disease.

Alembic Pharmaceuticals launches adapalene gel for acne vulgaris

Alembic Pharmaceuticals announces the launch of their bioequivalent and therapeutically equivalent product to Differin Gel 0.3% (Galderma), Adapalene Gel USP 0.3%, a topical retinoid for the treatment of acne vulgaris in patients 12 years and older.

Characteristics that distinguish facial hyperpigmentation disorders

Effective treatment first requires accurate diagnosis, one expert says. He offers tips to distinguish melasma from other disorders and suggests some patients may need to be checked for diabetes and metabolic syndrome if they exhibit certain presentations.

Sunscreen demonstrates strong therapeutic properties in patients with pigmentary disorders

The importance of blocking visible light in the treatment of pigmentary disorders is becoming clearer. One expert says photoprotection in patients with pigmentary conditions is a therapeutic cornerstone.

MC2 Therapeutics collaborates EPI Health on newly approved psoriasis topical

MC2 Therapeutics and EPI Health announce they have entered into a collaboration agreement for the commercialization of calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064% (Wynzora Cream), a newly U.S. FDA-approved topical treatment for plaque psoriasis in adults.

What dermatologists should know about blastic plasmacytoid dendritic cell neoplasm

One expert who is part of a small worldwide group of dedicated scientists and clinicians working to build BPDCN awareness among specialists offers insights from his research for dermatologists.

The Cutaneous Connection: Episode 6- Addressing the Need for Skin of Color Representation in Medical Education

In this episode, UIC medical students Kayla Clark and Gina Alvarado Jones, along with UIC Dermatology Department Head Maria Tsoukas, M.D. Ph.D., discuss their recently published analysis in JAAD, which takes a look at skin of color representation in medical education.

Tagraxofusp comparable to other chemo regimens as first-line therapy

Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.